Recruitment unclearEUCTR 2009-011253-40
Current recruitment status is unconfirmed.
This older record does not confirm current recruitment. No matching public CTIS record was confirmed using this identifier. Ask the research team for an up-to-date source.
In ItalyBipolarity, DepressionHistorical research record
- Countries
- Italy
- Sponsor
- AZIENDA SANITARIA OSPEDALIERA "S. GIOVANNI BATTISTA DI TORINO"
Not recruitingISRCTN50788919
This study isn't currently recruiting.
In United KingdomBipolarityResearch study
- Countries
- United Kingdom
- Sponsor
- University of Oxford (UK) (University)
Not recruitingISRCTN17054996
This study isn't currently recruiting.
In United KingdomBipolarity, DepressionResearch study
- Countries
- United Kingdom
- Sponsor
- University of Oxford (UK) (University)
Not recruitingISRCTN72019945
This study isn't currently recruiting.
In United KingdomBipolarity, SchizophreniaResearch study
- Countries
- United Kingdom
- Sponsor
- Lancaster University
CompletedNCT02363738
Official study titleA Multisite, Fixed Dose, Randomized, Double-Blind, Placebo-Controlled 12-Week Study Evaluating the Efficacy, Safety, and Tolerability of Adjunctive Infliximab for the Treatment of Bipolar I/II Depression
This study has finished and is no longer accepting participants.
Multiple locations, including Palo AltoBipolarity, DepressionMedication studyAges 18–65
- Countries
- United States, Canada
- Sponsor
- University Health Network, Toronto
SuspendedNCT04031469
Official study titleA Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
Recruitment is currently suspended.
In VenturaOCD, Bipolarity, ...Observational studyAges 12+
- Countries
- United States
- Sponsor
- ProgenaBiome
CompletedNCT01986101
What is this study about?Researchers compared SM-13496 and placebo to find out how the approaches affected depression symptoms in people with bipolarity type I during a depressive episode.
This study has finished and is no longer accepting participants.
Multiple locations, including TokyoBipolarity, DepressionMedication studyAges 18–74
- Countries
- Japan, Lithuania, Malaysia, + 5 others
- Sponsor
- Sumitomo Pharma Co., Ltd.
CompletedNCT03774641
Official study titleA Pilot Study of Prophylactic Management of Lamotrigine for Bipolar Disorder in Pregnant Women
This study has finished and is no longer accepting participants.
In BaltimoreDepression, BipolarityObservational studyAges 18+
- Countries
- United States
- Sponsor
- Johns Hopkins University
CompletedNCT00282464
Official study titleA Six-Week, Double-Blind, Multicenter, Placebo-Controlled Study Evaluating the Efficacy and Safety of Flexible Doses of Oral Ziprasidone in Outpatients With Bipolar I Depression
This study has finished and is no longer accepting participants.
Multiple locations, including DothanBipolarity, DepressionMedication studyAges 18+
- Countries
- United States
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00141271
Official study titleA Six-Week, Randomized, Double-Blind, Multicenter, Fixed-Flexible Dose, Placebo-Controlled Study Evaluating the Efficacy and Safety of Oral Ziprasidone in Outpatients With Bipolar I Depression
This study has finished and is no longer accepting participants.
Multiple locations, including BirminghamBipolarity, DepressionMedication studyAges 18+
- Countries
- United States
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
CompletedNCT00167479
Official study titleA Randomized, Double-Blind, Placebo-Controlled Study of Risperidone Monotherapy in Ambulatory Bipolar Disorder With Current at Least Moderately Severe Anxiety and Lifetime Panic Disorder or Generalized Anxiety Disorder
This study has finished and is no longer accepting participants.
Multiple locations, including TampaBipolarity, AnxietyMedication studyAges 18+
- Countries
- United States
- Sponsor
- University of South Florida
CompletedNCT07549581
Official study titleA Phase 1b, Randomized, Double-blind, Placebo-controlled Trial to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Oral Doses of SEP-380135 in Adults With Schizophrenia or With a Major Depressive Episode Associated With Bipolar I or II Disorder or Major Depressive Disorder
This study has finished and is no longer accepting participants.
In Los AlamitosDepression, Schizophrenia, ...Medication studyAges 18–55
- Countries
- United States
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)